Scientific Programme

To view the final programme and the accepted abstracts please click here

To view this page in Spanish, click here
To view this page in Portuguese, click here

Thursday 19 April 2018

09.00-09.15Official Opening
Juan Sierra Madero, Mexico City, Mexico and Mauro Schechter, Rio de Janeiro, Brazil

09.15-10.45Role of Integrase Inhibitors in LATAM: Are We Ready for First Line?
Co-chairs: Juan Sierra Madero and Mauro Schechter

09.15-09.35Current role of integrase inhibitors in Latin American guidelines
Ernesto Martinez Buitrago, Santiago de Cali, Colombia

09.35-09.55Observational studies with integrase inhibitors and experience with
first-line use in Brazil

Ricardo Diaz, São Paulo, Brazil

09.55-10.15The public health response to rising pre-treatment HIV drug
resistance levels in Latin America: the case of Mexico

Santiago Avila-Rios, Mexico City, Mexico



11.00-12.00Keynote Lectures
Co-chairs: Anton Pozniak, London, UK and Monica Thormann, Santo Domingo,
Dominican Republic

11.00-11.30What is needed to end HIV/AIDS?
Demetre Daskalakis, New York, USA

11.30-12.00What we mean in our region by ending AIDS?
Jean W Pape, Port-au-Prince, Haiti

12.00-13.30TB Diagnosis and Treatment: An Update for the Region
Co-chairs: Massimo Ghidinelli, Washington DC, USA and Marcelo Losso, Buenos Aires,

12.00-12.20New methods for TB diagnosis
Rafael López, Washington DC, USA

12.20-12.40Treatment for drug-resistant TB
Anton Pozniak, London, UK

12.40-12.55First-hand experience from Brazil: lessons learned
Ezio Távora Dos Santos-Filho, Rio de Janeiro, Brazil

12.55-13.10Safety and efficacy of dolutegravir-based ART in TB/HIV
co-infected adults at week 24
Eduardo Ticona, Lima, Peru


13.30-14.45Scientific Posters and Lunch

14.45-15.45Keynote Lectures
Co-chairs: Pedro Cahn, Buenos Aires, Argentina and Patricia Volkow, Mexico City,

14.45-15.15The microbiome in HIV infection
Sandra Pinto-Cardoso, Mexico City, Mexico

15.15-15.45Early treatment of HIV in infants
Karin A Nielsen, Los Angeles, USA

15.45-16.40Women with HIV in Latin America
Co-chairs: Pedro Cahn and Patricia Volkow

15.45-16.05Diagnosis and treatment of HIV positive women with comorbidities
Mónica Mantilla Suárez, Bogotá, Colombia

16.05-16.25ARV safety in pregnancy
Vanessa Rouzier, Port-au-Prince, Haiti

16.25-16.40HIV-infected pregnant adolescents are an extremely vulnerable population:
a cohort study of PMTCT outcomes
Marie M Deschamps, Port-au-Prince, Haiti


17.00-18.30Gilead Sciences Satellite Symposium 
Chair: Luis Soto-Ramirez, Mexico City, Mexico

Luis Soto-Ramirez, Mexico City, Mexico

17.05-17.30Current situation of regional efforts at screening, diagnosing and linking to care
Ernesto Martínez-Buitrago

17.30-17.55The current and future status of regional ART guidelines
Alejandro Afani, Santiago de Chile, Chile

17.55-18.20The value of INSTI- and TAF-containing STRs in both naive and switch patients
Luis Soto-Ramirez


18.30-19.15Welcome Reception and Posters

Friday 20 April 2018

09.00-10.30Merck Sharp & Dohme Satellite Symposium
Chair: Mauro Schechter

09.00-09.10Opening and welcome
Mauro Schechter

09.10-09.30Comorbidities and the need for total patient care
Mauro Schechter

09.30-09.50How resistance patterns influence individual treatment choices
José Luis Blanco, Barcelona, Spain

09.50-10.10The importance of tailoring HIV regimens to the individual patient
Pedro Cahn

10.10-10.25Clinical cases/faculty round table discussion
Led by Mauro Schechter

10.25-10.30Closing remarks
Mauro Schechter


10.45-11.15Keynote Lecture
Co-chairs: Ernesto Martínez Buitrago and Ian Weller, London, UK

10.45-11.15Update on PEP and on its role in the era of PrEP
Dawn Smith, Atlanta, USA

11.15-11.55HIV and Vulnerable Populations
Co-chairs: Ernesto Martínez Buitrago and Ian Weller

Benjamim Braga, Rio de Janeiro, Brazil

Daisy Machado, São Paulo, Brazil

11.55-13.00  Scientific Posters and Lunch

13.00-14.45Hepatitis C. New Drugs and What Can We Learn from HIV?
Co-chairs: Mario Pessoa, São Paulo, Brazil, and Alicia Piñeirúa, Mexico City, Mexico

13.00-13.20New HCV drugs in the region
Mark Nelson, London, UK

13.20-13.40Home/self-testing: how in HIV? When and to whom?
Omar Sued, Buenos Aires, Argentina

13.40-14.00Translating lessons from HIV to hepatitis C
Jorge Santana, San Juan, Puerto Rico

14.00-14.15   Risk factors for transmission of hepatitis C virus among HIV population in
Central Mexico: a case-control study
Luis Esteban Ramírez-Gonzalez, Mexico City, Mexico


15.00-15.30    Coffee

15.15-15.30Submitted Abstract
Chair: Roy M Gulick

15.15-15.30   Switch to bictegravir/F/TAT from DTG and ABC/3TC
Monica Mora, Foster City, CA, USA

15.30-17.00State of the ART
Co Chairs: Carlos J Beltran, Santiago, Chile and Roy Gulick 

15.30-15.50Dual therapy
Pedro Cahn, Buenos Aires, Argentina

15.50-16.20HIV and new drugs
Daniel Kuritzkes, Boston, USA


17.00-17.15Submitted Abstract and CROI Review
Chair: Ricardo Sobhie Diaz

17.00-17.15Transmitted drug resistance trends in individuals with recent infection in
the Mesoamerican Region
Daniela Tapia-Trejo, Mexico City, Mexico

17.15-17.45CROI 2018: What’s New?
Luis Soto-Ramirez, Mexico City, Mexico

17.45-18.00  Coffee

18.00-19.00Gilead Sciences Satellite Symposium
Chair: Juan Sierra-Madero

Juan Sierra-Madero

18.05-18.25HCV elimination program: strategies in Latin America
Mario Pessoa

18.25-18.45Pangenotypic regimen: a step forward in HCV treatment
Adrian Gadano, Buenos Aires, Argentina

Led by Juan Sierra-Madero

19.00-19.45Reception and Posters

Saturday 21 April 2018

09.00-10.30Challenging Cases in HIV:Interactive Case Study Session
In collaboration with International Antiviral Society-USA (IAS-USA)
Moderator: Roy Gulick

09.00-09.30What to start?
Brenda Crabtree-Ramirez, Mexico City, Mexico

09.30-10.00Treatment Failure
Carlos J Beltran, Santiago, Chile

Kenneth Mayer, Boston, USA


10.45-12.15Perspectives in Public Health “Old STIs – New Challenges”
In collaboration with the Pan American Health Organization (PAHO)

10.45-11.05Historic perspectives and public health significance of syphilis and other
STIs(gonococcal infection and non-gonococcal urethritis)

Massimo Ghidinelli and Maeve B Mello, Washinton DC, USA

11.05-11.20Syphilis amongst key populations
Mary Kamb, Atlanta, USA

11.20-11.35Innovation: Community based STI clinic and interventions in San Francisco
Jeffrey Klausner, San Francisco, USA

11.35-11.50  Outcomes of HIV and syphilis infection amoung pregnant women in Haiti
Marie M. Deschamps, Port-au-Prince, Haiti



12.30-14.15Update on Pre-Exposure Prophylaxis(PrEP)
In collaboration with the International AIDS Society (IAS)
Co-chairs: Brenda Crabtree-Ramirez and Mauro Schechter

12.30-12.50PrEP: from clinical trials to implementation
Kenneth Mayer, Boston, USA

12.50-13.10HIV prevention: PrEP situation in Latin American countries
Giovanni Ravasi, Washington DC, USA

13.10-13.30PrEP of HIV in Mexico: adding colour to the prevention palette
Hugo Lopez-Gatell, Mexico City, Mexico


14.15-14.30Conference Close